ERBB2 and breast carcinoma: Recently, Scaltriti et al. demonstrated that gene amplification and overexpression of CCNE1 were associated with resistance of trastuzumab treatment for breast cancer [32], suggesting that cell cycle check-point system by CCNE is a key function for HER2-positive breast cancer.